EFFECT OF DISEASE AND DRUG-TREATMENT ON BLOOD SEROTONIN AND MONOAMINE-OXIDASE-B ACTIVITY IN PARKINSONS-DISEASE

被引：4
|
作者：
VANKEMPEN, GMJ [1 ]
JANJUA, R [1 ]
ROOS, RAC [1 ]
机构：
[1] LEIDEN STATE UNIV,ACAD HOSP,DEPT NEUROL,2333 AA LEIDEN,NETHERLANDS
来源：
CLINICAL NEUROLOGY AND NEUROSURGERY | 1995年 / 97卷 / 02期
关键词：
DRUG EFFECTS; 5-HYDROXYTRYPTAMINE; MONOAMINE OXIDASE; PARKINSONS DISEASE; SELEGILINE; SEROTONIN;
D O I：
10.1016/0303-8467(95)00011-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Serotonin (5-hydroxytryptamine, 5HT) content and monoamine oxidase (MAO) activity were determined in whole blood of patients with Parkinson's disease (PD) with and without drug treatment and compared with controls. From that comparison a significant reduction in platelet 5HT became apparent in PD. Selegiline, which was always used in combination with L-dopa, not only inhibited MAO activity, as expected, but it also appeared to induce an increase in 5HT content.
引用
收藏
页码：131 / 133
页数：3
相关论文
共 50 条
  • [31] Phytochemical screening and effect of Viscum album L. on monoamine oxidase A and B activity and serotonin, dopamine and serotonin receptor 5-HTR1A levels in Galleria mellonealla (Lepidoptera)
    Szurpnicka, Anna
    Wronska, Anna Katarzyna
    Bus, Katarzyna
    Kozinska, Aleksandra
    Jablczynska, Renata
    Szterk, Arkadiusz
    Lubelska, Katarzyna
    JOURNAL OF ETHNOPHARMACOLOGY, 2022, 298
  • [32] (-)-DEPRENYL TREATMENT OF PATIENTS WITH PARKINSONS-DISEASE DOES NOT AFFECT ERYTHROCYTE CATECHOL-O-METHYL TRANSFERASE-ACTIVITY
    RUSS, H
    GERLACH, M
    DETTNER, O
    KUHN, W
    PRZUNTEK, H
    JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1991, 3 (03) : 215 - 223
  • [33] Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study
    Mendzelevski, Boaz
    Sprenger, Craig R.
    Spiegelstein, Ofer
    Rabinovich-Guilatt, Laura
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (03) : 192 - 201
  • [34] Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease
    Chen, Jack J.
    Ly, Anh-Vuong
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (10) : 915 - 928
  • [35] Discovery of novel benzimidazole derivatives as selective and reversible monoamine oxidase B inhibitors for Parkinson's disease treatment
    Lv, Yangjing
    Fan, Miaoliang
    He, Jiayan
    Song, Xiaoxin
    Guo, Jianan
    Gao, Bianbian
    Zhang, Jingqi
    Zhang, Changjun
    Xie, Yuanyuan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 274
  • [36] PLASMA CLOZAPINE LEVELS AND THE TREATMENT OF L-DOPA-INDUCED PSYCHOSIS IN PARKINSONS-DISEASE - A HIGH POTENCY EFFECT OF CLOZAPINE
    MELTZER, HY
    KENNEDY, J
    DAI, J
    PARSA, M
    RILEY, D
    NEUROPSYCHOPHARMACOLOGY, 1995, 12 (01) : 39 - 45
  • [37] Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease
    Jolene Ooi
    Michael R. Hayden
    Mahmoud A. Pouladi
    Molecular Neurobiology, 2015, 52 : 1850 - 1861
  • [38] Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease
    Ooi, Jolene
    Hayden, Michael R.
    Pouladi, Mahmoud A.
    MOLECULAR NEUROBIOLOGY, 2015, 52 (03) : 1850 - 1861
  • [39] Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
    Matthias Löhle
    Heinz Reichmann
    BMC Neurology, 11
  • [40] Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
    Loehle, Matthias
    Reichmann, Heinz
    BMC NEUROLOGY, 2011, 11
12345